The partnership addresses the worldwide increase in focus on drug safety, which is leading to increased volumes of adverse events being reported to the regulatory authorities. Satyam and Sciformix will collaborate to enable pharmaceutical and biotechnology companies to better monitor the safety of the products they market by offering services across the safety management spectrum, ranging from case intake to international regulatory reporting.
The alliance also enables the organisations to offer these services in a way that is both cost-efficient and scaleable, via a proven global delivery model.
Additionally, the alliance leverages Sciformix's in-depth understanding of the pharmaceutical and life sciences domain with Satyam's proven drug safety business process outsourcing (BPO) capabilities. It will provide services to a wide range of clients in the pharmaceutical, biotechnology and life sciences industries.
